Reports Q3 revenue $14.2M, consensus $4.65M. “Lexicon (LXRX) ushered in 2025 with an ambitious slate of objectives embracing and driving our renewed R&D focus,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “As we approach year-end, I’m pleased and proud of our significant R&D, operational and partnering accomplishments so far this year. We expect 2026 to be a pivotal year as these strategic initiatives progress with the potential to create lasting value for our stakeholders.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- LXRX Earnings this Week: How Will it Perform?
- Lexicon Pharmaceuticals: Promising Phase 2b Results and Strategic Plans Justify Buy Rating
- Lexicon presents additional pilavapadin data in DPNP
- Lexicon convenes roundtable on public policy gaps for chronic pain
- FDA informs Lexicon it requires additional time to review Zynquista NDA